Literature DB >> 1696401

Pleuroperitoneal shunt for recurrent malignant pleural effusions.

V Tsang1, H C Fernando, P Goldstraw.   

Abstract

The therapeutic options available for the management of malignant pleural effusions associated with a restricting malignant cortex remain unsatisfactory. The efficacy of pleuroperitoneal shunts was evaluated in 16 patients with recurrent malignant effusions. There were no operative deaths; one patient died on the third postoperative day as a result of lymphangitis carcinomatosa. The median hospital stay was five (range 3-21) days. Palliation was obtained in all but one of the other 15 patients. There was no appreciable reaccumulation of pleural fluid as judged by radiography. Two patients developed occlusion of the shunt. In one case this was due to blood clots in the pleural catheter and necessitated insertion of a new shunt. The other shunt was removed because of obstructing infected fibrin debris, and a rib resection was performed. There were eight deaths related to the underlying malignancy after a mean interval of 7.3 (range 1.5-23) months. The other six patients are still alive, with a mean survival of 11.0 (range 5-20) months, and have achieved good symptomatic relief. The insertion of a pleuroperitoneal shunt can offer effective palliation for patients with recurrent malignant pleural effusions.

Entities:  

Mesh:

Year:  1990        PMID: 1696401      PMCID: PMC462476          DOI: 10.1136/thx.45.5.369

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  8 in total

1.  Pleuroperitoneal shunting for recalcitrant pleural effusions.

Authors:  G E Cimochowski; L R Joyner; R Fardin; R Sarama; A Maran
Journal:  J Thorac Cardiovasc Surg       Date:  1986-11       Impact factor: 5.209

2.  The treatment of malignant pleural effusions.

Authors:  C B Anderson; G W Philpott; T B Ferguson
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

3.  Pleural peritoneal shunts for the treatment of malignant pleural effusions.

Authors:  J L Weese; J T Schouten
Journal:  Surg Gynecol Obstet       Date:  1982-03

4.  Clinicopathological observations on metastasis in man studied in patients treated with peritoneovenous shunts.

Authors:  D Tarin; J E Price; M G Kettlewell; R G Souter; A C Vass; B Crossley
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-10

5.  Indications for pleurectomy in malignant effusion.

Authors:  N Martini; M S Bains; E J Beattie
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

6.  The treatment of resistant malignant ascites by insertion of a peritoneo-atrial Holter valve.

Authors:  A V Pollock
Journal:  Br J Surg       Date:  1975-02       Impact factor: 6.939

7.  Chylothorax: an assessment of current surgical management.

Authors:  J W Milsom; I L Kron; K S Rheuban; B M Rodgers
Journal:  J Thorac Cardiovasc Surg       Date:  1985-02       Impact factor: 5.209

8.  Effective treatment of malignant pleural effusions.

Authors:  I S Fentiman
Journal:  Br J Hosp Med       Date:  1987-05
  8 in total
  5 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

2.  Parietal pleurectomy for malignant pleural effusion.

Authors:  W A Fry; J D Khandekar
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

Review 3.  Management of Malignant Lung Entrapment, the Oncothorax.

Authors:  Roman Petrov; Charles Bakhos; Abbas E Abbas
Journal:  Thorac Surg Clin       Date:  2018-02       Impact factor: 1.750

4.  Efficacy of short term versus long term tube thoracostomy drainage before tetracycline pleurodesis in the treatment of malignant pleural effusions.

Authors:  A G Villanueva; A W Gray; D M Shahian; W A Williamson; J F Beamis
Journal:  Thorax       Date:  1994-01       Impact factor: 9.139

5.  How should cancer presenting as a malignant pleural effusion be managed?

Authors:  H Bonnefoi; I E Smith
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.